Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
You may also be interested in...
Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
Dealmaking Quarterly Statistics, Q2 2020
During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.
Financing Quarterly Statistics, Q2 2020
During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.
Need a specific report? 1000+ reports available
Buy Reports